Lamivudine Teva (Lamivudine)

Lamivudine is converted inside cells to its active triphosphate form, which mimics natural nucleosides. When incorporated into viral DNA by reverse transcriptase or HBV polymerase, it terminates the growing DNA chain, thereby blocking viral replication.

The specific dose of lamivudine is determined by the prescribing clinician based on the patient’s condition, age, renal function and treatment regimen. Patients should follow the dose prescribed by their healthcare professional.

Safety data for lamivudine in pregnancy and lactation are limited. The drug may be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Lamivudine Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with a favorable safety profile and once‑daily dosing options. Compared with older NRTIs, it has lower mitochondrial toxicity and is often combined with other classes such as protease inhibitors or integrase inhibitors to achieve potent viral suppression.

Lamivudine Teva should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Lamivudine Teva is taken orally, usually with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious adverse events associated with lamivudine include lactic acidosis, severe hepatotoxicity, pancreatitis, bone marrow suppression and severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unexplained fatigue, abdominal pain, jaundice, rash or respiratory distress.

Lamivudine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with severe renal impairment, active liver disease, or those receiving medications that have major interacting potential.